GlassScriptPhysician profile
Julie Torman
NPI 1285729764
$1,137.08
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $18.34 · 2021: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $296.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.86 | 2019 | |
| Abbvie INC. | $173.15 | 2019-2021 | |
| Corcept Therapeutics | $112.13 | 2019 | |
| Braintree Laboratories, INC. | $57.23 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $38.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.28 | 2019 | |
| Shire North American Group INC | $36.49 | 2019 | |
| Janssen Biotech, INC. | $30.58 | 2021 | |
| Electromed, INC. | $29.36 | 2019 | |
| Mylan Specialty L.P. | $25.12 | 2019 | |
| Sk Life Science, INC. | $13.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.17 | 2019 | |
| Amarin Pharma, INC. | $12.78 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.40 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.37 | 2019 | |
| Allergan, INC. | $11.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Torman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.